

ASX Announcement | 7 May 2026
AdAlta Limited (ASX:1AD)

**Investor Webinar: New hope for mesothelioma patients -
BZDS1901 clinical update**

AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products will host a virtual investor webinar on 11 May 2026.

AdAlta’s CEO and Managing Director, Dr Tim Oldham will discuss:

- The rapidly lethal nature of mesothelioma, a cancer infamously associated with asbestos exposure.
- Early results from clinical studies of AdAlta’s BZDS1901 product suggesting it has the potential to significantly improve response rates and even achieve rare complete tumour clearances in advanced mesothelioma patients
- The cutting edge CAR-T technology that enables BZDS1901 to achieve these results
- The potential value of BZSD1901 to large pharma partners if these early results are replicated in Australian clinical trials
- How BZDS1901 exemplifies AdAlta’s “East to West” strategy

The presentation will be followed by an opportunity for investor questions.

Webinar details are:

Monday, 11 May 2026

2:30 – 3:15 pm AEST

Register (free) here: <https://investorhub.adalta.com.au/webinars/vPna9r-new-hope-for-mesothelioma-patients-bzds1901-car-t-clinical-overview>

This ASX announcement has been authorised for release by the CEO of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham

CEO & Managing Director

P: +61 3 9479 5159

E: t.oldham@adalta.com.au

About AdAlta

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its subsidiary company, AdCella Pty Ltd's 'East to West' strategy, the Company is integrating Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting 'Eastern' innovation in cellular immunotherapies with 'Western' regulated markets and patients.

AdCella in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdCella implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdCella aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdCella's first asset, BZDS1901, is a first in class CAR-T cell therapy for mesothelioma and other solid cancers including lung and gynaecological cancers. BZDS1901 is the first CAR-T product for mesothelioma to secrete its own immune checkpoint inhibitor "armouring" to help overcome tumour immune suppression, is manufactured in less than two days without expensive viral vectors, and has demonstrated clinical potential, including difficult to achieve complete responses in advanced mesothelioma in China.

Separately, AdAlta's first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering. AdAlta's first in class i-body®, WD-34, is a discovery stage asset being advanced through partnering as a potentially transformational prophylaxis and treatment for malaria.

To learn more, please visit: www.adalta.com.au

For more information



Join our [InvestorHub](#)



Follow us on [LinkedIn](#)



Follow us on [X \(formerly Twitter\)](#)